In this paper (Gonzalez et al., Org. Process Res. Dev. 2019, 23, 6, 1143-1151) from the Chemical and Synthetic Development team at Bristol-Myers Squibb, DoE and QbD methodologies have been used to develop a telescoped process for the API step in the route to a reversible inhibitor of BTK. (Scheme 1) Scheme 1: Two step